Correlation Between Pfizer and Innate Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pfizer and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pfizer and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pfizer Inc and Innate Pharma, you can compare the effects of market volatilities on Pfizer and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pfizer with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pfizer and Innate Pharma.

Diversification Opportunities for Pfizer and Innate Pharma

0.77
  Correlation Coefficient

Poor diversification

The 3 months correlation between Pfizer and Innate is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Pfizer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pfizer Inc are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Pfizer i.e., Pfizer and Innate Pharma go up and down completely randomly.

Pair Corralation between Pfizer and Innate Pharma

Considering the 90-day investment horizon Pfizer Inc is expected to generate 0.25 times more return on investment than Innate Pharma. However, Pfizer Inc is 3.93 times less risky than Innate Pharma. It trades about -0.16 of its potential returns per unit of risk. Innate Pharma is currently generating about -0.12 per unit of risk. If you would invest  2,865  in Pfizer Inc on August 28, 2024 and sell it today you would lose (288.00) from holding Pfizer Inc or give up 10.05% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Pfizer Inc  vs.  Innate Pharma

 Performance 
       Timeline  
Pfizer Inc 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.
Innate Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pfizer and Innate Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pfizer and Innate Pharma

The main advantage of trading using opposite Pfizer and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pfizer position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.
The idea behind Pfizer Inc and Innate Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins